Disease Modification by Combinatorial Single Vector Gene Therapy: A Preclinical Translational Study in Epilepsy

Area of Science:

• Neuroscience
• Gene Therapy
• Epilepsy Research

Background:

• Focal epilepsy often shows poor response to traditional pharmacological treatments.
• Gene therapy presents a potential novel strategy for seizure control.
• Neuropeptide Y (NPY) and its Y2 receptor are implicated in seizure modulation.

Purpose of the Study:

• To evaluate the seizure-suppressant potential of a single-vector gene therapy combining neuropeptide Y and Y2 receptor.
• To assess the efficacy of adeno-associated virus serotype 1 (AAV1)-based gene therapy in a rat model of chronic epilepsy.

Main Methods:

• A dose-response study using kainate-induced seizures identified an optimal vector titer (10^12 genomic particles/mL).
• An efficacy study utilized MRI-guided hippocampal administration of the AAV1 vector in a chronic epilepsy model with spontaneous recurrent seizures (SRSs).

Main Results:

• The gene therapy achieved a 31% responder rate ( >50% reduction in SRS frequency) and a 13% seizure-freedom rate.
• Significant prolongation of inter-seizure intervals and SRS cluster intervals was observed.
• A significant reduction in seizure duration was noted in the treated group compared to controls.

Conclusions:

• Single-vector combinatorial neuropeptide Y/Y2 receptor gene therapy demonstrates significant seizure-suppressant ability.
• This approach shows promise as a clinically relevant treatment for chronic epilepsy.
• The findings support gene therapy as a viable option for focal epilepsy refractory to medication.